NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma

Leuk Res. 2011 Jun;35(6):715-20. doi: 10.1016/j.leukres.2011.01.018. Epub 2011 Feb 17.

Abstract

NT-proBNP provides diagnostic and prognostic information in heart syndromes but its role in cancer has not yet been established. The prognostic value of NT-proBNP was prospectively studied in 104 non-Hodgkin lymphoma (NHL) patients treated with chemotherapy. Echocardiography and NT-proBNP were determined prior to treatment. In multivariate analysis, NT-proBNP ≥ 900 pg/ml was the variable with higher risk of death (adjusted hazard ratio 11.1; 95% CI 3.8-32.9; P<0.001). The C statistic for NT-proBNP ≥ 900 pg/ml was significantly better than IPI score for prediction of survival. These findings suggest that NT-proBNP ≥ 900 pg/ml could be considered a useful marker for risk assessment in NHL patients treated with chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers / analysis*
  • Echocardiography
  • Female
  • Heart Diseases / diagnosis*
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Non-Hodgkin / diagnosis*
  • Lymphoma, Non-Hodgkin / diagnostic imaging
  • Lymphoma, Non-Hodgkin / drug therapy
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Natriuretic Peptide, Brain / analysis*
  • Peptide Fragments / analysis*
  • Predictive Value of Tests
  • Prognosis
  • Prospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Peptide Fragments
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain